Precision Wealth Strategies LLC Takes Position in Eli Lilly and Company $LLY

Precision Wealth Strategies LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 780 shares of the company’s stock, valued at approximately $608,000.

A number of other hedge funds have also recently bought and sold shares of the business. WestEnd Advisors LLC increased its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its position in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. JPMorgan Chase & Co. decreased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Guggenheim dropped their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $939.61.

Eli Lilly and Company Trading Up 8.2%

Shares of NYSE:LLY opened at $825.92 on Thursday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $781.70 billion, a PE ratio of 53.98, a P/E/G ratio of 1.06 and a beta of 0.47. The company’s 50-day moving average price is $733.71 and its 200 day moving average price is $766.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.